Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 4/20 | 0.41 |
| ▸ | FLT1 | P17948 | 3/20 | 0.40 |
| ▸ | FLT4 | P35916 | 3/20 | 0.40 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 3/20 | 0.36 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.35 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | SIRT7 | Q9NRC8 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16349127 | 0.92 | VCP (0.43) | VCPKDRFLT1FLT4IMPDH2 | |
| SCHEMBL5481749 | 0.89 | VCP (0.46) | VCPKDRFLT1FLT4IMPDH2 | |
| SCHEMBL5477719 | 0.86 | VCP (0.46) | VCPKDRFLT1FLT4IMPDH2 | |
| SCHEMBL5475253 | 0.86 | VCP (0.50) | VCPKDRFLT1FLT4IMPDH2 | |
| SCHEMBL5235804 | 0.85 | VCP (0.49) | VCPKDRFLT1FLT4IMPDH2 | |
| SCHEMBL5227541 | 0.83 | VCP (0.45) | VCPKDRFLT1FLT4IMPDH2 | |
| SCHEMBL5477651 | 0.82 | VCP (0.44) | VCPKDRIMPDH2BRD4EGFR | |
| SCHEMBL16349174 | 0.81 | VCP (0.45) | VCPKDRFLT1FLT4IMPDH2 | |
| SCHEMBL5469590 | 0.80 | CCNA2 (0.52) | VCPIMPDH2BRD4 | |
| SCHEMBL16349175 | 0.78 | KDR (0.45) | VCPKDRFLT1FLT4IMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1551813-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2007-07-11 | — | — | EP | claimed |
| US-20070142437-A1 | CHEMICAL COMPOUNDS | BROWN MATTHEW L | 2007-06-21 | — | — | US | claimed |
| US-20050288515-A1 | Chemical compounds | SMITHLINE BEECHAM CORPORATION | 2005-12-29 | — | — | US | claimed |
| EP-1551813-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-13 | — | — | EP | claimed |
| WO-2004032882-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-04-22 | — | — | WO | claimed |
| US-20070142437-A1 | CHEMICAL COMPOUNDS | BROWN MATTHEW L | 2007-06-21 | — | — | US | disclosed |
| US-20070142437-A1 | CHEMICAL COMPOUNDS | BROWN MATTHEW L | 2007-06-21 | — | — | US | disclosed |
| US-7189712-B2 | 1,3-Oxazole compounds for the treatment of cancer | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189712-B2 | 1,3-Oxazole compounds for the treatment of cancer | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-13 | — | — | US | disclosed |
| US-20050288515-A1 | Chemical compounds | SMITHLINE BEECHAM CORPORATION | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142437-A1 | CHEMICAL COMPOUNDS | CDK4, CDK2, CDK3 | VCP 3873/4885KDR 33/4885FLT1 56/4885 |
| US-20050288515-A1 | Chemical compounds | CDK4, CDK2, CDK3 | VCP 3873/4885KDR 33/4885FLT1 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.